Braeburn Pharmaceuticals, Inc.
Formerly AT Pharmaceuticals, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2018 | $110 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Braeburn Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2018).
SEC Form D · Jan 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2018
That is all the official record says: Braeburn Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Braeburn Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Asher M. Rubin | Secretary | Jan 2018 |
| David J. McIntyre | Chief Financial Officer and Treasurer | Jan 2018 |
| Michael Derkacz | Chief Executive Officer and President | Jan 2018 |
| Seth L. Harrison, M.D. | Chairman | Jan 2018 |
| Argeris L. Karabelas, Ph.D. | Director | Jan 2018 |
| Brian H. Markison | Director | Jan 2018 |
| Dennis H. Langer, J. D., M.D. | Director | Jan 2018 |
| Jeffrey L. Berkowitz | Director | Jan 2018 |
| Michael Derkacz | Chief Executive Officer and President | Jan 2018 |
| Patrick L. Kennedy | Director | Jan 2018 |
| Seth L. Harrison, M.D. | Chairman | Jan 2018 |